全文获取类型
收费全文 | 63110篇 |
免费 | 4881篇 |
国内免费 | 1857篇 |
专业分类
耳鼻咽喉 | 830篇 |
儿科学 | 1186篇 |
妇产科学 | 2215篇 |
基础医学 | 7984篇 |
口腔科学 | 1167篇 |
临床医学 | 6839篇 |
内科学 | 11695篇 |
皮肤病学 | 1190篇 |
神经病学 | 3927篇 |
特种医学 | 2631篇 |
外国民族医学 | 6篇 |
外科学 | 8495篇 |
综合类 | 4200篇 |
现状与发展 | 7篇 |
一般理论 | 11篇 |
预防医学 | 3382篇 |
眼科学 | 1394篇 |
药学 | 5385篇 |
20篇 | |
中国医学 | 1673篇 |
肿瘤学 | 5611篇 |
出版年
2023年 | 461篇 |
2022年 | 655篇 |
2021年 | 2129篇 |
2020年 | 1294篇 |
2019年 | 1613篇 |
2018年 | 1998篇 |
2017年 | 1516篇 |
2016年 | 1567篇 |
2015年 | 2332篇 |
2014年 | 2915篇 |
2013年 | 3403篇 |
2012年 | 4818篇 |
2011年 | 4695篇 |
2010年 | 2987篇 |
2009年 | 2616篇 |
2008年 | 3544篇 |
2007年 | 3637篇 |
2006年 | 3393篇 |
2005年 | 3136篇 |
2004年 | 2825篇 |
2003年 | 2706篇 |
2002年 | 2351篇 |
2001年 | 1856篇 |
2000年 | 1615篇 |
1999年 | 1340篇 |
1998年 | 563篇 |
1997年 | 479篇 |
1996年 | 435篇 |
1995年 | 380篇 |
1994年 | 360篇 |
1993年 | 258篇 |
1992年 | 719篇 |
1991年 | 599篇 |
1990年 | 537篇 |
1989年 | 496篇 |
1988年 | 423篇 |
1987年 | 423篇 |
1986年 | 357篇 |
1985年 | 297篇 |
1984年 | 229篇 |
1983年 | 193篇 |
1982年 | 113篇 |
1981年 | 123篇 |
1980年 | 100篇 |
1979年 | 206篇 |
1978年 | 162篇 |
1977年 | 103篇 |
1976年 | 110篇 |
1975年 | 101篇 |
1974年 | 99篇 |
排序方式: 共有10000条查询结果,搜索用时 281 毫秒
21.
22.
23.
Yu-Tzu Chan Alan C.-Y. Lai Ruey-Jen Lin Ya-Hui Wang Yi-Ting Wang Wen-Wei Chang Hsin-Yi Wu Yu-Ju Lin Wen-Ying Chang Jen-Chine Wu Jyh-Cherng Yu Yu-Ju Chen Alice L. Yu 《International journal of cancer. Journal international du cancer》2020,146(6):1674-1685
G protein-coupled estrogen receptor-1 (GPER), a member of the G protein-coupled receptor (GPCR) superfamily, mediates estrogen-induced proliferation of normal and malignant breast epithelial cells. However, its role in breast cancer stem cells (BCSCs) remains unclear. Here we showed greater expression of GPER in BCSCs than non-BCSCs of three patient-derived xenografts of ER−/PR+ breast cancers. GPER silencing reduced stemness features of BCSCs as reflected by reduced mammosphere forming capacity in vitro, and tumor growth in vivo with decreased BCSC populations. Comparative phosphoproteomics revealed greater GPER-mediated PKA/BAD signaling in BCSCs. Activation of GPER by its ligands, including tamoxifen (TMX), induced phosphorylation of PKA and BAD-Ser118 to sustain BCSC characteristics. Transfection with a dominant-negative mutant BAD (Ser118Ala) led to reduced cell survival. Taken together, GPER and its downstream signaling play a key role in maintaining the stemness of BCSCs, suggesting that GPER is a potential therapeutic target for eradicating BCSCs. 相似文献
24.
25.
2019年12月始,新型冠状病毒肺炎(Corona Virus Disease 2019,COVID-19)以湖北武汉为中心向全国各地蔓延。目前数据显示,COVID-19合并糖尿病、高血压、肿瘤等基础病的患者病情较为严峻,病死率相对较高。该类患者的临床治疗策略有待进一步深入研究。在此次疫情防治过程中,中西医结合治疗手段于COVID-19的防治及患者基础疾病的兼顾治疗方面展现出了一定的特色及优势。本文结合中医“未病先防,既病防变,瘥后防复”思想,拟从COVID-19合并糖尿病、高血压、肿瘤三个方面,探讨COVID-19爆发形势下合并基础病患者的中医药防治策略。 相似文献
26.
Fei Xu Ming‐Liang Ye Yu‐Peng Zhang Wen‐Jie Li Meng‐Ting Li Hai‐Zhou Wang Xiao Qiu Yan Xu Jin‐Wen Yin Qian Hu Wan‐Hui Wei Ying Chang Lan Liu Qiu Zhao 《Cancer science》2020,111(5):1528-1541
Resistance to chemotherapy is a major challenge for the treatment of patients with colorectal cancer (CRC). Previous studies have found that microRNAs (miRNAs) play key roles in drug resistance; however, the role of miRNA‐373‐3p (miR‐375‐3p) in CRC remains unclear. The current study aimed to explore the potential function of miR‐375‐3p in 5‐fluorouracil (5‐FU) resistance. MicroRNA‐375‐3p was found to be widely downregulated in human CRC cell lines and tissues and to promote the sensitivity of CRC cells to 5‐FU by inducing colon cancer cell apoptosis and cycle arrest and by inhibiting cell growth, migration, and invasion in vitro. Thymidylate synthase (TYMS) was found to be a direct target of miR‐375‐3p, and TYMS knockdown exerted similar effects as miR‐375‐3p overexpression on the CRC cellular response to 5‐FU. Lipid‐coated calcium carbonate nanoparticles (NPs) were designed to cotransport 5‐FU and miR‐375‐3p into cells efficiently and rapidly and to release the drugs in a weakly acidic tumor microenvironment. The therapeutic effect of combined miR‐375 + 5‐FU/NPs was significantly higher than that of the individual treatments in mouse s.c. xenografts derived from HCT116 cells. Our results suggest that restoring miR‐375‐3p levels could be a future novel therapeutic strategy to enhance chemosensitivity to 5‐FU. 相似文献
27.
Xue Yao Yan Zhang Jian Hao Hui-Quan Duan Chen-Xi Zhao Chao Sun Bo Li Bao-You Fan Xu Wang Wen-Xiang Li Xuan-Hao Fu Yong Hu Chang Liu Xiao-Hong Kong Shi-Qing Feng 《中国神经再生研究》2019,(3)
Ferroptosis is an iron-dependent novel cell death pathway. Deferoxamine, a ferroptosis inhibitor, has been reported to promote spinal cord injury repair. It has yet to be clarified whether ferroptosis inhibition represents the mechanism of action of Deferoxamine on spinal cord injury recovery. A rat model of Deferoxamine at thoracic 10 segment was established using a modified Allen's method. Ninety 8-week-old female Wistar rats were used. Rats in the Deferoxamine group were intraperitoneally injected with 100 mg/kg Deferoxamine 30 minutes before injury. Simultaneously, the Sham and Deferoxamine groups served as controls. Drug administration was conducted for 7 consecutive days. The results were as follows:(1) Electron microscopy revealed shrunken mitochondria in the spinal cord injury group.(2) The Basso, Beattie and Bresnahan locomotor rating score showed that recovery of the hindlimb was remarkably better in the Deferoxamine group than in the spinal cord injury group.(3) The iron concentration was lower in the Deferoxamine group than in the spinal cord injury group after injury.(4) Western blot assay revealed that, compared with the spinal cord injury group, GPX4, xCT, and glutathione expression was markedly increased in the Deferoxamine group.(5) Real-time polymerase chain reaction revealed that, compared with the Deferoxamine group, mRNA levels of ferroptosis-related genes Acyl-CoA synthetase family member 2(ACSF2) and iron-responsive element-binding protein 2(IREB2) were up-regulated in the Deferoxamine group.(6) Deferoxamine increased survival of neurons and inhibited gliosis. These findings confirm that Deferoxamine can repair spinal cord injury by inhibiting ferroptosis. Targeting ferroptosis is therefore a promising therapeutic approach for spinal cord injury. 相似文献
28.
Clinical clues for differential diagnosis between verruca plana and verruca plana‐like seborrheic keratosis 下载免费PDF全文
Won‐Jeong Kim Won‐Ku Lee Margaret Song Hoon‐Soo Kim Hyun‐Chang Ko Byung‐Soo Kim Moon‐Bum Kim 《The Journal of dermatology》2015,42(4):373-377
Sometimes the clinical differentiation between verruca plana (VP) and VP‐like seborrheic keratosis (SK) could be challenged. However, there have been no studies on this issue to date. The aim of this study was to elucidate clinical and dermoscopic differences between these two diseases, and also to suggest a diagnostic algorithm of VP and VP‐like SK without skin biopsy. The patients who had lesions clinically considered as VP or VP‐like SK were the target of our study. We took clinical and dermoscopic photos with informed consent and conducted a questionnaire. All patients had their diagnoses confirmed by biopsy. Thirty‐three patients were enrolled in our study. Seventeen patients were finally diagnosed with VP (51.5%) and 16 patients with VP‐like SK (48.5%). In clinical findings, VP‐like SK showed significantly more scattered distribution than VP (P = 0.039), which exhibited more clustered or grouped distribution (P = 0.039). In dermoscopic findings, brain‐like appearance was more commonly observed in VP‐like SK (P = 0.003) whereas VP showed more red dots or globular vessels (P = 0.017) and even‐colored light brown to yellow patch (P < 0.001). Sex, onset age, the size of each lesion, location, color and shape showed no significant differences between them (P > 0.05). Based on our results, we suggest a diagnostic algorithm using Koebner's phenomenon, dermoscopic findings, distribution of each lesion and biopsy for multiple VP‐like lesions in adults, and we think it will be a very useful diagnostic tool in daily clinical dermatological practice. 相似文献
29.
30.
Fur-Hsing Wen Jen-Shi Chen Wen-Chi Chou Wen-Cheng Chang Wen Chi Shen Chia-Hsun Hsieh Siew Tzuh Tang 《Journal of pain and symptom management》2019,57(1):64-72